Penn Medicine Abramson Cancer Center

 

Penn Medicine Abramson Cancer Center
G

IO for Pancreatic Cancer: Microenvironment and Resistance Mechanisms, Importance of Sequencing Therapies for IO, and Targeting Metastases

By Penn Medicine Abramson Cancer Center FEATURING Gregory Beatty
By Penn Medicine Abramson Cancer Center FEATURING Gregory Beatty
654 views
November 22, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Immunotherapy
16:30
Penn Medicine Abramson Cancer Center

New Immunotherapy Discoveries for NSCLC: What Are Available Approach…

Feat. C. Aggarwal
18:16
Penn Medicine Abramson Cancer Center

The Promise of Proton and Stereotactic Radiation Therapy for Early a…

Feat. S. Feigenberg
22:23
Penn Medicine Abramson Cancer Center

IO for Pancreatic Cancer: Microenvironment and Resistance Mechanisms…

Feat. G. Beatty
09:58
Penn Medicine Abramson Cancer Center

How do you make T-cells better?

Feat. C. June
08:13
Penn Medicine Abramson Cancer Center

Challenges and Opportunities with CAR T-cells

Feat. C. June
05:15
Penn Medicine Abramson Cancer Center

Combinatorial Cancer Immunotherapies

Feat. C. June
10:07
Penn Medicine Abramson Cancer Center

Using CAR T in Solid Tumors?

Feat. C. June
08:18
Penn Medicine Abramson Cancer Center

The Making of the Tisagenlecleucel CAR T

Feat. C. June
31:49
Penn Medicine Abramson Cancer Center

CD 19 CAR T-cells in Leukemia

Feat. S. Grupp